<DOC>
	<DOCNO>NCT01333111</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe , Japan North America . The aim trial evaluate safety efficacy , include pharmacokinetics ( rate body eliminate trial drug ) , NNC-0156-0000-0009 ( nonacog beta pegol ) use treatment prophylaxis bleed episode patient haemophilia B .</brief_summary>
	<brief_title>Safety Efficacy NNC-0156-0000-0009 Haemophilia B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Male patient moderately severe severe congenital haemophilia B factor IX activity 2 % accord medical record History least 150 exposure day factor IX product Patients currently treat ondemand least 6 bleed episode last 12 month least 3 bleed episode last 6 month , patient currently prophylaxis Known history factor IX inhibitor base exist medical record , laboratory report review patient legally acceptable representative ( LAR ) interview HIV ( Human immunodeficiency virus ) positive , viral load equal 400,000 copies/mL and/or CD4+ lymphocyte count equal 200/microL Congenital acquire coagulation disorder haemophilia B Previous arterial thrombotic event ( e.g . myocardial infarction intracranial thrombosis ) previous deep venous thrombosis pulmonary embolism ( define available medical record ) Immune modulate chemotherapeutic medication</criteria>
	<gender>Male</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>